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Background: To evaluate the clinical features, treatment results, prognostic factors and late toxicities of nasopharyngeal
carcinoma in children and adolescents.
Methods: Between January 1990 and January 2011, 158 NPC patients younger than 20 years old were treated in our
institution, and the patient’s clinical characteristics, treatment modalities, outcomes and prognostic factors were
retrospectively analyzed.
Results: There were 9 (5.7%) patients in stage II, 60 (38.0%) in stage III and 89 (56.3%) in stage IV according to the
UICC2002 staging system. Neck mass (32.3%), headache (21.5%) and nasal obstruction (15.2%) were the most common
chief complaints. With a median follow-up time of 62.5 months (range 2.0-225.0 months), the 5-year overall survival (OS)
rate, local-regional control (LRC) rate and distant metastasis-free survival (DMFS) rate were 82.6%, 94.9% and 76.4%,
respectively. There were 43 (27.2%) patients failed during the follow up, with seven local-regional recurrences and 38
distant metastases. In univariate analysis, the 5-year OS of T4 and T1-3 were 75% and 87.9%, p = 0.01, stage IV and stage
II-III were 77.1% and 90%, p = 0.04, respectively. In multivariate analysis, T4 (p = 0.02) and stage IV (p = 0.04) were the
independent adverse prognostic factors for OS. Significant reduction in trismus (27.3% v 3.6%, p = 0.03) and G2
xerostomia (37.9% v 10.3%, p = 0.02) was observed in patients treated by IMRT.
Conclusions: Most childhood and adolescence nasopharyngeal carcinoma patients were locally advanced diseases at
first diagnosed. The treatment results of radiotherapy, with or without chemotherapy, are excellent in our institution.
Reducing distant metastasis with new strategies and late toxicities with intensity-modulated radiotherapy are the future
directions for the treatment of adolescent nasopharyngeal carcinoma.
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Nasopharyngeal carcinoma (NPC) is the most com-
monly diagnosed head and neck malignancy in China
and Southeast Asian countries, but children and adoles-
cent nasopharyngeal carcinoma is very rare worldwide.
The incidence among children and adolescents varies
greatly among different regions and races, accounts for
0.1-2.3% of all NPCs in our nation [1,2] and 2%-18% in
other countries [3-5]. Standard therapy for NPC in* Correspondence: yijunlin1969@163.com
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unless otherwise stated.children and adolescents has generally followed the
guidelines established for adults. External beam radio-
therapy has been the mainstay of such treatment, and
concurrent chemoradiotherapy has been confirmed to
be effective in adult patients [4]. The published results
of NPC in the young are diverse, most involving a small
number of patients, non-uniform regimens both in
radiotherapy and chemotherapy. Although childhood
and adolescence NPC patients are usually associated
with advanced local-regional disease at first diagnoses and
a highly prevalence of distant metastasis, the outcomes
are generally better than adult NPC [5,6]. In this paper, we
collected a large sample size with relative homogenousThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment results, prognostic factors and late toxicities. We
hope to provide further information on the treatment of




Between January 1, 1990 and January 31, 2011, 168 patho-
logically confirmed NPC patients under 20 years old were
treated in our institution. Ten patients were excluded due
to their undefined stage or lost follow-up shortly after treat-
ment. The median age was 16 years (range 8–20 years). All
patients received thorough physical examinations, biopsies
of the nasopharynx, dental care, general status evaluations,
blood counts, chest X-rays, as well as neck and abdomen
ultrasonography. Indirect mirrors (n = 158,100%) and
fiberoptic nasopharyngoscopes (n = 72, 45.6%) were used to
examine the nasopharynx. All patients were restaged
according to the UICC 2002 staging system. 153 patients
(96.8%) were staged with either CT, MRI or both, among
them, 76 patients (48.1%) had bone scans before treatment.
X-rays and clinical examinations were used in the other five
as staging tools.
Treatment
All patients received radical external beam radiotherapy,
there were 24 (15.2%) patients received neoadjuvant
chemotherapy, 43 (27.2%) patients in stage III/IV received
concurrent chemo-radiotherapy and 20 (12.7%) patients
with residue primary lesions after radiotherapy received
adjuvant chemotherapy.
Radiotherapy
There were 103 (65.2%) patients received conventional
2D radiotherapy using 6 MV photons combined with
6–12 MeV electrons. The technique and dose used were
as follows: first, a facial-cervical field (encompassing the
nasopharynx, paranasopharyngeal fissure, skull base, pter-
ygopalatine fossa, one third to one half of the posterior
nasal cavity and maxillary sinus, and the upper neck
lymph drainage region; usually the inferior margin of the
field was set at the lower edge of hyoid bone) to a total
dose of 36 Gy, followed by a smaller facial-cervical field
(when the tumor involved the oropharynx or retropharyn-
geal lymph node) or a preauricular field to avoid excessive
exposure of the brainstem and the spinal cord, to a total
dose of 70–72 Gy to the nasopharyngeal region. The
irradiation dose to the neck lymph node drainage region
was as follows: 50 Gy was delivered to the lower neck and
supraclavicular region and 60 Gy to the upper neck when
cervical nodes were negative. 60 Gy were applied to the
entire neck and supraclavicular region when cervical
nodes were positive, then 70–72 Gy to the positive lymphnodes, with the division of the upper and lower neck set
at the lower edge of the cricoid bone. After 70–72 Gy of
irradiation, an additional of 10–21 Gy was boosted to the
residue tumor with a shrinking-field external beam,
brachytherapy or stereotactic radiosurgery technique. The
residual lymph nodes were removed by surgical excision
or regional neck dissection after 2–3 months observation.
There were 55 (34.8%) patients received intensity-
modulated radiation therapy (IMRT) technique. The entire
neck IMRT technique was used to cover the primary
lesion, nodal disease and entire neck including the supra-
clavicular region. The prescription dose for T1 and T2
primary lesions (GTVp) was 70 Gy in 33 fractions at
2.12 Gy per fraction, while 74 Gy at 2.24 Gy per fraction
was applied to T3 or T4 diseases and involved retrophar-
yngeal nodes with a maximum diameter > 1.5 cm, and all
positive lymph nodes (GTVnd) received 70 Gy at 2.12 Gy
per fraction. The elective radiation dose of 60 Gy at
1.82 Gy per fraction encompassed the high-risk regions in-
cluding the uninvolved skull base, parapharyngeal spaces,
the posterior third of the nasal cavity and high-risk nodal
levels. If there were no positive neck nodes in the neck,
50–54 Gy was delivered to the bilateral lower neck and
supraclavicular region using a two-phase IMRT plan, with
the phase 1 IMRT plan (28 treatment fractions) covering
the primary lesion, positive nodes, the high-risk region
and the lower neck/supraclavicular region. The phase 2
IMRT plan (5 treatment fractions) covered only the pri-
mary lesion, positive nodes and high-risk regions. The
dose limited to the major organs at risk were as follows:
the brain stem with a 3 mm margin, Dmax < 54 Gy; spinal
cord with a 5 mm margin, Dmax < 40 Gy; the optic nerve,
chiasm and temporal lobe, Dmax < 54 Gy; and the parotid
gland, V30-35 < 50%.
For patients who received neoadjuvant chemotherapy,
the target volumes depended on the pre-chemo involved
regions.
Chemotherapy
Seventy (44.3%) patients received chemotherapy, with 24,
43 and 20 patients treated by neoadjuvant, concurrent and
adjuvant chemotherapy, respectively. Neoadjuvant chemo-
therapy consisted of cisplatin and a 5-FU based regimen
(PF regimen) every 3 weeks for 1–2 cycles. In concurrent
chemotherapy, 34 patients received a cisplatin 30 mg/m2/
week regimen (median cycles: 7), 9 patients received
cisplatin 80–100 mg/m2/q3w regimen (median cycles: 3),
and adjuvant chemotherapy were PF-based regimen for
2–6 cycles.
Intra- and Post- treatment assessments
All patients were evaluated weekly during radiation ther-
apy, with a required follow-up after they completed radio-
therapy: one month after the completion of radiotherapy,
Table 1 The characteristics of patients
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Combined modality therapy 73(46.2)
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from the second to fifth years, and annually thereafter.
Late radiation effects were evaluated and scored according
to the Radiation Therapy Oncology Group/European
Organization for Research and Treatment of Cancer late
effects scale.
Statistical analysis
The statistic was performed by SPSS 19.0 software.
Kaplan-Meier method was used for calculating the
survival, chi-square test and Cox regression analysis were
used to detect statistically significant differences among
the late toxicities and potential prognostic factors between
the different groups.
Ethical statement
This study has been approved by ethics committee of
cancer hospital, Chinese academy of Medical Sciences.
Results
Patients’ clinicopathological characteristics
Among 158 patients eligible for analysis, there were 119
male and 39 female, with median age of 16 years old
(range 8–20 years), 9 patients in stage II, 60 in stage III
and 89 in stage IV, respectively. 139 (88%) patients were
non-keratinizing diseases. The median history time was
4.8 months (range 0.2-60.0 months). Neck mass (32.3%),
headache (21.5%) and nasal obstruction (15.2%) were the
most common chief complaints. There were 36 patients
(22.8%) observed cranial nerve palsy, the grigeminal
nerve (V) and abducent nerve (VI) were the most com-
monly involved, with incidence of 7.6% in V1 (12), 12.0%
in V2 (19), 10.1% in V3 (16) and 6.3% in VI repectively
(Table 1).
Survival and prognostic factors
The median follow-up time was 62.5 months (range 2.0-
225.0 months), with 13.3% patients lost follow-up. The
5-year OS, LRC and DMFS were 82.6%, 94.9% and
76.4%, respectively (Figure 1). In univariate analysis
(Table 2), the 5-year OS of T4 and T1-3 were 75% and
87.9%, p = 0.01, stage IV and stage II-III were 77.1% and
90%, p = 0.04, respectively. In multivariate analysis, T4
(p = 0.02) and stage IV (p = 0.04) were the independent
adverse prognostic factors for OS. No significant prog-
nostic factors were found for LRC and DMFS in either
univariate or multivariate analysis.
Failure pattern
There were 43 patients (27.2%) failed during follow up,
with 7 in local-regional, 38 in distant metastasis and 2 in
both. The median failure times were 15 months (3–39
months) and 5 months (1–38 months) for local-regional
recurrence and distant metastasis. The most commonsite of metastasis was bone (27 patients, 17.1%); other sites
included lung (n = 7), liver (n = 1) and distant lymph
nodes (n = 3). The causes of death were primary disease in
24, second malignancy in 2 and unknown in 4.
Late toxicities
For those patients who had detail medical records, the
most common late toxicities were xerostomia, neck fibro-
sis, and hearing loss, with incidence of 94.8% (55/58), 91.2%
(52/57) and 52.6% (30/57) respectively. Hypothyroidism
was reported in 50.8% (30/59) patients. Severe late sequela
Figure 1 Kaplan-Meier survival curves of 158 children and
adolescents nasopharyngeal carcinoma. The 5-year overall survival
(OS), local-regional control (LRC) and distant metastasis free survival
(DMFS) were 82.6%, 94.9% and 76.4%, respectively.








Gender 0.43 0.48 0.07
Male 81.1 93.9 73.0
Female 86.6 97.4 86.6
Age 0.17 0.54 0.76
≤16 78.4 95.6 77.2
>16 87.5 94.0 75.5
History 0.45 0.98 0.92
≤6 m 80.5 94.7 77.1
>6 m 87.7 95.2 74.7
UICC-T
0.80 0.67 0.99
T1 66.7 100 75.0
T2-4 82.9 94.7 76.5
0.34 0.77 0.64
T1-2 83.3 93.1 78.7
T3-4 82.3 95.4 75.7
0.01 0.32 0.54
T1-3 87.9 96.2 76.9
T4 75.0 92.9 75.7
UICC-N
0.95 0.48 0.30
N0 77.1 100 90.0
N1-3 82.9 94.5 75.4
0.48 0.10 0.19
N0-1 89.6 100 83.3
N2-3 79.9 92.8 73.8
0.51 0.61 0.45
N0-2 83.8 95.6 75.2
N3 77.8 92.6 81.2
UICC stage
0.57 0.53 0.36
II 85.7 100 88.9
III-IV 82.4 94.6 75.7
0.04 0.10 0.87
II-III 90.0 98.4 75.9
IV 77.1 92.0 76.9
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necrosis (2 ptatients) and nasopharynx hemorrhage (1 pa-
tient). Due to a lack of sufficient information, radiation
encephalopathy could not be fully documented (see detail
in Table 3). When compared to the patients treated by 2D
conventional technique, significant reduction in trismus
(27.3% v 3.6%, p = 0.03) and G2 xerostomia (37.9% v 10.3%,
p = 0.02) was observed in those patients treated by IMRT.
There were six patients (3.8%) developed second
primary neoplasm in the radiation field after 38–123
months of radiotherapy (Table 4).
Discussion
The incidence of NPC varies widely among different re-
gions and races, and is most often seen among patients
in their fifth or sixth decade in endemic countries. How-
ever, there was a bimodal incidence graphs in sporadic
regions such as North America and Mediterranean basin
countries, a second minor early peak was observed at
10–20 years of age, with incidence of 2-18% [7]. Huang
et al. [1] reported the number of patients younger than
15 years old was 53 (0.1%) among 54,304 NPC patients
in China. Our group accounted for 1.33% of all NPC
patients from 1990–2011 (total 3,081 patients). Similar
to adults, the children and adolescents with NPC in our
study usually presented with neck masses, headaches, tin-
nitus and cranial nerve palsy. On the other hand, children
and adolescents patients had a higher proportion of non-
keratinization carcinoma (88%) and advanced diseases
(stage III-IV, 94.3%). This result was similar to other
reports, with non-keratinizing carcinoma accounted for
71.4%-96.4% of all patients, and stage III-IV patients con-
stituted 78.5%-96% [6-12]. In our study, the 5-year OS,
LRC and DMFS of 82.6%, 94.9% and 76.4%, respectively,
were higher than in other studies with a 5-year OS ranging
from 49%-79% and a 5-year DFS varying from 47%-73%
[2,4,6,8,9,11-14]. The higher survival rate may result from
higher radical radiation dose and a boost dose to the
Table 2 Univariate analysis (log-rank test) (Continued)
Yes 87.3 100 78.6




Yes 85.3 97.6 78.8




Yes 90.0 89.7 80.0
No 72.9 100 75.9
Technology 0.33 0.74 0.42
2D 79.5 94.2 74.0
IMRT 88.7 96.1 81.1
Dose 0.45 0.45 0.63
>70 Gy 86.8 93.7 74.2
≤70 Gy 77.1 96.6 79.4
Response 0.11 0.21 0.46
PR 75.2 92.1 74.5
CR 89.2 97.2 79.4
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studies found that children and adolescent NPC patients
have better results compared with adult NPC patients, the
5 years OS were 71% v 58% (p = 0.03) [6] and the 5 years
disease-specific survival were 83% ± 3.9% v 62% ± 0.8%
(p < 0.001) [5].Table 3 Late toxicities
Technique Grade 0 (%) Grade 1 (
Skin (n = 54) IMRT(19) 3(15.8) 14(73.7)
2D(35) 12(34.3) 18(51.4)
Mucosa (n = 55) IMRT(20) 14(70.0) 5(25.0)
2D(35) 15(42.9) 17(48.6)
Neck fibrosis (n = 57) IMRT(21) 3(14.3) 8(38.1)
2D(36) 2(5.6) 15(41.7)
Xerostomia (n = 58) IMRT(21) 1(4.7) 14(66.7)
2D(37) 2(5.4) 13(35.1)
Spinal cord (n = 49) IMRT(18) 18(100) 0
2D(31) 30(96.8) 1(3.2)
Hearing (n = 57) IMRT(20) 10(50.0) 0
2D(37) 17(45.9) 0
Vision (n = 53) IMRT(18) 17(94.4) 1(5.6)
2D(35) 32(91.4) 1(2.9)
Trismus (n = 55) IMRT(18) 16(88.9) 0
2D(37) 22(59.5) 0
Hypothyroidism (n = 59) IMRT(39) 19(48.7) 0
2D(20) 10(50.0) 0In our univariate and multivariate analysis, T4 was the
adverse prognostic factor. T4 patients usually have a
larger tumor volume than those with T1-3 and a higher
tumor burden needs a higher dose to control. Sze et al.
[17] found that the correlation between T stage and tumor
volume was a highly significant factor among 308 naso-
pharyngeal carcinoma patients, and the risk of local failure
was estimated to increase by 1% for every 1 cm3 increase
in primary tumor volume. Although the recommended
dose for the primary site ranges from 59.4 Gy to 66 Gy
(1.8-2.0 Gy per fraction) in the literature, it seems that a
higher dose provided better outcomes; Ozyar et al. [8] re-
ported that dose > 66 Gy had promising LRRFS (p = 0.01)
in multivariate analysis, while other authors reported that
a 64-80Gy or higher dose was needed [2,18]. In contrast,
Hu et al. [13] reported that higher radiation dose (>
70 Gy) did not promise better local control or survival,
and some authors believed that higher dose would inevit-
ably damage normal tissue, causing a high incidence of se-
vere late sequelae and second malignancies [7,10]. In our
study, the incidence of common late complications, such
as xerostomia, neck fibrosis, hearing loss and trismus,
were similar to or slightly lower than in other reports
[2,10,13,14]. Wolden et al. [10] found that neither the
addition of chemotherapy nor the radiation dose was statis-
tically predictive for adverse sequelae. However, there was a
slight trend toward fewer severe complications when 3D
conformal radiotherapy and IMRT were used compared
with 2D conventional radiation techniques (0% v 28%).
Laskar et al. [19] reported a significant reduction in the%) Grade 2 (%) Grade 3 (%) Grade 4 (%) p value
2(10.5) 0 0 0.377
4(11.4) 1(2.9) 0
1(5.0) 0 0 0.152
3(8.6) 0 0
8(38.1) 2(9.5) 0 0.672
12(33.3) 6(16.7) 1(2.8)
6(28.6) 0 0 0.063
22(59.5) 0 0
0 0 0 0.441
0 0 0
10(50.0) 0 0 0.568
18(48.6) 0 2(5.4)
0 0 0 0.530
0 0 2(5.7)
1(5.6) 1(5.6) 0 0.091
12(32.4) 1(2.7) 2(5.4)
20(51.3) 0 0 0.926
10(50.0) 0 0
Table 4 Second primary neoplasm
Gender Age Onset
year







M 17 1992 T3N2M0 RT 2D 72.5 + 10※ 80/62 116 Lower jaw
bone
NA
F 16 2000 T2N2M0 RT + CT 2D 70 + 6※ 70/50 48 Neck Fibrosarcoma
M 11 1994 T4N3M0 RT 2D 74 66/52 119 Maxillary sinus Fibrosarcoma
M 16 1995 T2N3M0 RT 2D 70 + 16※ 70/70 37 Soft palate Papilloma
F 12 1998 T4N2M0 RT 2D 70 70/60 153 Cervical
vertebra
NA
M 16 1996 T4N1M0 RT 2D 70 70/60 101 Upper jaw
bone
Chondrosarcoma
※was boosted by SRS or IMRT or cone down field.
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longation in the median time to the onset of Grade 2 tox-
icity with IMRT. Our study showed consistent findings of
prevention in late toxicity by using IMRT. The use of IMRT
resulted in a significant reduction of trismus (p = 0.03) and
G2 xerostomia (p = 0.02) because of IMRT allows for the
delivery of high doses to the target area while sparing the
surrounding critical structures and offers superior target
coverage compared with conventional radiotherapy and
3D-CRT in improving therapeutic ratios. Using new tech-
niques, such as IMRT, to improve local control and protect
normal tissue will be a key focus in future daily practice.
Many studies focused on using neoadjuvant chemother-
apy combined with lower dose radiotherapy to reduce the
radiation related severe late toxicities. In NPC-91-GPOH
study and NPC-2003-GPOH/DCOG study [20,21], after
combination of chemotherapy and radiation (54–59.4 Gy)
followed by INF-β-1a, complete remesion was accomplished
in 58/59 and 43/45 of patients, and excellent disease-free
survival and overall survival were achieved in advanced
NPC patients. In Orbach’s retrospective study, the 5 year
OS and EFS of patients who had a good response to neoad-
juvant chemotherapy with a low radiation dose (≤50 Gy)
were 74% and 76%, so the author proposed that a reduction
radiation dose to chemo-sensitive patients was feasible [22].
In the present series of young NPC patients, distant me-
tastasis remained the major pattern of failure [2,12,20],
which indicated that subclinical metastasis had already
existed at first treatment, requiring early systemic therapy.
However, the most effective chemotherapy regimens and
their optimal timing with radiation therapy remained to
be determined. Due to the rare incidence rate of children
and adolescent nasopharyngeal carcinoma, multi-center
collaboration on RCTs is needed to establish the treat-
ment guidelines for pediatric NPCs.Conclusion
Most childhood and adolescence nasopharyngeal patients
had local advanced diseases at first diagnosed. Thetreatment results of radiotherapy with or without chemo-
therapy are excellent in our institution. Reducing distant
metastasis with new strategies and late toxicities with
intensity-modulated radiotherapy will be the future direc-
tions for the treatment of children and adolescent nasopha-
ryngeal carcinoma. Further, response-adapted RT is worth
further evaluation to minimize late toxicities.
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